title: [Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis].
abstract: BACKGROUND
  Bacterial conjunctivitis is characterized by hyperemia and discharge of one or both eyes. These clinical signs appear quickly and are contagious. This study compares the clinical efficacy (signs and symptoms) and safety of azithromycin 1.5% eye drops with tobramycin 0.3%.
  
  
  METHODS
  This was a multicenter, randomized, investigator-masked study including 1,043 patients with purulent bacterial conjunctivitis. Patients received either azithromycin twice daily for 3 days or tobramycin, 1 drop every 2 hours for 2 days, then four times daily for 5 days. The primary variable was clinical cure at the test-of-cure (TOC) visit (D9) on the worst eye. The cure was defined as bulbar conjunctival injection and discharge scores of 0. Clinical signs were evaluated at D0, D3, and D9.
  
  
  RESULTS
  In the azithromycin group 87.8% of patients and in the tobramycin group 89.4% were clinically cured at D9. Clinical cure with azithromycin was not inferior to tobramycin at D9: discharge was absent in 96.3% of patients treated with azithromycin and 95.1% with tobramycin. Azithromycin was well tolerated.
  
  
  CONCLUSIONS
  Azithromycin 1.5% for 3 days (six drops) was as effective as tobramycin for 7 days (36 drops). Furthermore, patients on azithromycin presented earlier clinical cure on Day 3 than patients on tobramycin. Azyter, with its convenient dosing (bid for 3 days), is a step forward in the management of purulent bacterial conjunctivitis.
authors.affiliation: Service d'Ophtalmologie, CHU Dupuytren, 2, avenue Martin Luther King, 87042 Limoges Cedex, France. pierre-yves.robert@unilim.fr
authors.forename: P-Y
authors.initials: PY
authors.lastname: Robert
authors.forename: T
authors.initials: T
authors.lastname: Bourcier
authors.forename: A
authors.initials: A
authors.lastname: Meddeb-Ouertani
authors.forename: M
authors.initials: M
authors.lastname: Khairallah
authors.forename: K
authors.initials: K
authors.lastname: Zaghloul
authors.forename: A
authors.initials: A
authors.lastname: Amraoui
authors.forename: Y
authors.initials: Y
authors.lastname: Bhagat
authors.forename: M
authors.initials: M
authors.lastname: Pop
authors.forename: I
authors.initials: I
authors.lastname: Cochereau
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017963:Azithromycin / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003228:Conjunctiva / Q000187:drug effects; D003234:Conjunctivitis, Bacterial / Q000188:drug therapy* / Q000503:physiopathology; D004487:Edema / Q000188:drug therapy; D004890:Erythema / Q000188:drug therapy; D005141:Eyelid Diseases / Q000188:drug therapy; D005500:Follow-Up Studies; D006801:Humans; D006940:Hyperemia / Q000188:drug therapy; D007223:Infant; D007231:Infant, Newborn; D008875:Middle Aged; D009883:Ophthalmic Solutions; D012449:Safety; D016037:Single-Blind Method; D013492:Suppuration / Q000188:drug therapy; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D009883:Ophthalmic Solutions; D017963:Azithromycin; D014031:Tobramycin